CN102083439A - 使用TGF-β受体抑制剂或活化素样激酶(ALK)5抑制剂A-83-01和SB-431542治疗眼病与伤口愈合症状的方法 - Google Patents

使用TGF-β受体抑制剂或活化素样激酶(ALK)5抑制剂A-83-01和SB-431542治疗眼病与伤口愈合症状的方法 Download PDF

Info

Publication number
CN102083439A
CN102083439A CN2009801199382A CN200980119938A CN102083439A CN 102083439 A CN102083439 A CN 102083439A CN 2009801199382 A CN2009801199382 A CN 2009801199382A CN 200980119938 A CN200980119938 A CN 200980119938A CN 102083439 A CN102083439 A CN 102083439A
Authority
CN
China
Prior art keywords
composition
inhibitor
kinase
activin receptor
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801199382A
Other languages
English (en)
Chinese (zh)
Inventor
H·纳卡穆拉
B·Y·J·T·岳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Summa Health Systems LLC
Original Assignee
Summa Health Systems LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Summa Health Systems LLC filed Critical Summa Health Systems LLC
Publication of CN102083439A publication Critical patent/CN102083439A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2009801199382A 2008-05-30 2009-05-29 使用TGF-β受体抑制剂或活化素样激酶(ALK)5抑制剂A-83-01和SB-431542治疗眼病与伤口愈合症状的方法 Pending CN102083439A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5746108P 2008-05-30 2008-05-30
US61/057461 2008-05-30
PCT/US2009/045607 WO2009146408A1 (en) 2008-05-30 2009-05-29 Methods for using tgf-b receptor inhibitors or activin-like kinase (alk) 5 inhibitors a-83-01 and sb-431542 to treat eye disease and wound healing conditions

Publications (1)

Publication Number Publication Date
CN102083439A true CN102083439A (zh) 2011-06-01

Family

ID=41377599

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801199382A Pending CN102083439A (zh) 2008-05-30 2009-05-29 使用TGF-β受体抑制剂或活化素样激酶(ALK)5抑制剂A-83-01和SB-431542治疗眼病与伤口愈合症状的方法

Country Status (5)

Country Link
US (1) US20100087486A1 (enExample)
EP (1) EP2285380A4 (enExample)
JP (1) JP2011521969A (enExample)
CN (1) CN102083439A (enExample)
WO (1) WO2009146408A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106282092A (zh) * 2016-09-07 2017-01-04 山东省眼科研究所 一种角膜内皮分离和扩增培养液

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100267731A1 (en) * 2009-04-17 2010-10-21 Summa Health Systems, LLC Use of transforming growth factor-b receptor inhibitors to suppress ocular scarring
RU2013111281A (ru) * 2010-08-17 2014-09-27 Аллерган, Инк. Агонисты ер2 или ер4 для лечения помутнения роговицы
RU2018145985A (ru) 2012-11-02 2019-02-18 Селджин Корпорейшн Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
JP6461787B2 (ja) 2013-04-12 2019-01-30 国立大学法人京都大学 肺胞上皮前駆細胞の誘導方法
US9822342B2 (en) 2013-05-14 2017-11-21 Kyoto University Method of efficiently inducing cardiomyocytes
MX386503B (es) 2013-07-30 2025-03-19 Kyoto Prefectural Public Univ Corp Medicamentos terapeuticos de matriz extracelular endotelial corneal.
WO2015020113A1 (ja) 2013-08-07 2015-02-12 国立大学法人京都大学 膵ホルモン産生細胞の製造法
EP3042951B1 (en) 2013-09-05 2019-02-20 Kyoto University New method for inducing dopamine-producing neural precursor cells
CA2927898C (en) 2013-10-31 2021-11-16 Kyoto Prefectural Public University Corporation Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
US10472610B2 (en) 2014-05-21 2019-11-12 Kyoto University Method for generating pancreatic bud cells and therapeutic agent for pancreatic disease containing pancreatic bud cells
CA3005975A1 (en) 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders
US11898163B2 (en) 2016-04-22 2024-02-13 Kyoto University Method for producing dopaminergic neuron progenitor cell
CA3064830A1 (en) 2017-05-25 2018-11-29 Kyoto University Method for inducing differentiation of intermediate mesodermal cell to renal progenitor cell, and method for inducing differentiation of pluripotent stem cell to renal progenitor cell
WO2019160148A1 (ja) 2018-02-19 2019-08-22 大日本住友製薬株式会社 細胞凝集体、細胞凝集体の混合物及びそれらの製造方法
WO2020022261A1 (ja) 2018-07-23 2020-01-30 国立大学法人京都大学 新規腎前駆細胞マーカーおよびそれを利用した腎前駆細胞の濃縮方法
CA3140384A1 (en) 2019-05-15 2020-11-19 Ajinomoto Co., Inc. Method for purifying neural crest cells or corneal epithelial cells
EP3974519A4 (en) 2019-05-20 2023-07-12 Ajinomoto Co., Inc. EXPANSION CULTURE METHOD FOR CARTILAGE OR BONE PRECURSOR CELLS
US12533383B2 (en) 2019-09-06 2026-01-27 Keio University Method for producing cell aggregate including glial progenitor cells
EP4043553A4 (en) 2019-10-01 2023-11-22 Kyoto University METHOD FOR ISOLATING URETERAL NODLE CELLS
CA3175573A1 (en) 2020-03-19 2021-09-23 Orizuru Therapeutics, Inc. Cardiomyocyte purification method
US20230212519A1 (en) 2020-03-19 2023-07-06 Orizuru Therapeutics, Inc. Method for purifying cardiomyocytes
JP7429294B2 (ja) 2020-07-13 2024-02-07 国立大学法人京都大学 骨格筋前駆細胞及びその精製方法、筋原性疾患を治療するための組成物、並びに骨格筋前駆細胞を含む細胞群の製造方法
CN116802276A (zh) 2021-01-08 2023-09-22 国立大学法人京都大学 用于扩增培养肾元祖细胞的培养基、扩增培养肾元祖细胞的方法以及肾脏类器官的制造方法
CA3222761A1 (en) 2021-06-10 2022-12-15 Ajinomoto Co., Inc. Method for producing mesenchymal stem cells
JPWO2022265086A1 (enExample) 2021-06-17 2022-12-22
WO2023286852A1 (ja) 2021-07-15 2023-01-19 株式会社セルファイバ 構造体及びその用途
EP4386083A4 (en) 2021-08-11 2025-11-12 Univ Kyoto METHOD FOR PRODUCING RENAL INTERSTITIAL PROGENITOR CELLS, ERYTHROPOIETIN-PRODUCING CELLS AND METHOD FOR PRODUCING RENIIN-PRODUCING CELLS
EP4471126A4 (en) 2022-02-01 2026-01-14 Univ Kyoto LUNG MESENCHYMAL CELLS AND PROCESS FOR PRODUCING LUNG MESENCHYMAL CELLS
WO2023153464A1 (ja) 2022-02-09 2023-08-17 住友ファーマ株式会社 多能性幹細胞から中脳底板領域の神経系細胞への分化における、培養液中の細胞の分化能を判定する方法
WO2023228908A1 (ja) 2022-05-23 2023-11-30 国立大学法人京都大学 腎集合管細胞および腎盂上皮細胞の製造方法
CN119948151A (zh) 2022-09-26 2025-05-06 国立大学法人京都大学 胰腺内胚层细胞的制造方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470881A (en) * 1993-09-09 1995-11-28 West Virginia University Research Corporation Urea ophthalmic ointment and solution
JPH08503969A (ja) * 1993-09-29 1996-04-30 アルコン ラボラトリーズ，インコーポレイテッド 増殖因子と組織形成抑制剤を含有する組成物
WO1995009003A1 (en) * 1993-09-29 1995-04-06 Alcon Laboratories, Inc. Compositions containing growth factors and antimetabolites
US5449671A (en) * 1993-09-29 1995-09-12 Alcon Laboratories, Inc. Use of TGF-β3, to prevent or retard fistula closure following glaucoma filtration surgery
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
US6063396A (en) * 1994-10-26 2000-05-16 Houston Biotechnology Incorporated Methods and compositions for the modulation of cell proliferation and wound healing
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
WO2003057670A2 (en) * 2001-12-28 2003-07-17 Guilford Pharmaceuticals Inc. Indoles as naaladase inhibitors
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
EP1581222A2 (en) * 2003-01-02 2005-10-05 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-&bgr;
ATE398125T1 (de) * 2003-03-12 2008-07-15 Millennium Pharm Inc Chinazolin-derivate als tgf-beta-inhibitoren
US7314939B2 (en) * 2003-06-17 2008-01-01 Millennium Pharmaceuticals, Inc. Compositions and methods for inhibiting TGF-β
KR100749566B1 (ko) * 2004-04-21 2007-08-16 이화여자대학교 산학협력단 Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
US20050256118A1 (en) * 2004-05-12 2005-11-17 Altenbach Robert J Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US7098222B2 (en) * 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US20060234911A1 (en) * 2005-03-24 2006-10-19 Hoffmann F M Method of reversing epithelial mesenchymal transition
BRPI0619966A2 (pt) * 2005-12-16 2011-10-25 Alcon Inc controle de pressão intra-ocular usando agentes de modulação de alk5
BRPI0714409A2 (pt) * 2006-07-14 2013-03-12 Novartis Ag derivados de pirimidina como inibidores de alk-5
US7524640B2 (en) * 2006-08-06 2009-04-28 Children's Medical Center Corporation Inhibiting Smad2/3 signaling promotes neurite outgrowth in dorsal root ganglia

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106282092A (zh) * 2016-09-07 2017-01-04 山东省眼科研究所 一种角膜内皮分离和扩增培养液

Also Published As

Publication number Publication date
EP2285380A4 (en) 2012-03-14
WO2009146408A9 (en) 2010-12-02
WO2009146408A1 (en) 2009-12-03
JP2011521969A (ja) 2011-07-28
EP2285380A1 (en) 2011-02-23
US20100087486A1 (en) 2010-04-08

Similar Documents

Publication Publication Date Title
CN102083439A (zh) 使用TGF-β受体抑制剂或活化素样激酶(ALK)5抑制剂A-83-01和SB-431542治疗眼病与伤口愈合症状的方法
Morales et al. Intraoperative mitomycin and corneal endothelium after photorefractive keratectomy
Frucht-Pery et al. Conjunctival autografting combined with low-dose mitomycin C for prevention of primary pterygium recurrence
Heuer et al. 5-fluorouracil and glaucoma filtering surgery: II. A pilot study
Belknap Corneal emergencies
Bian et al. Dexamethasone drug eluting nanowafers control inflammation in alkali-burned corneas associated with dry eye
US20100267731A1 (en) Use of transforming growth factor-b receptor inhibitors to suppress ocular scarring
Huang et al. Combination of dexamethasone and Avastin® by supramolecular hydrogel attenuates the inflammatory corneal neovascularization in rat alkali burn model
US20040216749A1 (en) Vasomodulation during glaucoma surgery
CN105050600B (zh) 眼底疾病治疗剂
TW201729813A (zh) 青光眼預防或治療之藥物療法
EP3808352A1 (en) Use of salidroside and derivative thereof in preparation of inhibitor medicament for diseases of ophthalmic fibrosis caused by abnormalities of extracellular matrix proteins
Sapitro et al. Suppression of transforming growth factor-β effects in rabbit subconjunctival fibroblasts by activin receptor-like kinase 5 inhibitor
Kerr et al. Primary needling of the ab interno gelatin microstent reduces postoperative needling and follow-up requirements
KR20010040457A (ko) 안약 조성물
Feusier et al. Deep sclerectomy combined with trabeculectomy in pediatric glaucoma
JP2016514123A (ja) ジピリダモールを用いる眼疾患の治療において使用するための組成物
Vantesone et al. Effects of topical diclofenac and prednisolone eyedrops in laser in situ keratomileusis patients
Evereklioglu et al. Aqueous humor adrenomedullin levels differ in patients with different types of glaucoma
Nassiri et al. Comparison of 2 surgical techniques in phacotrabeculectomy: 1 site versus 2 sites
Wang et al. AGTR1 blocker attenuates activation of Tenon's capsule fibroblasts after glaucoma filtration surgery via the NF-κB signaling pathway
EP2842557A1 (en) Mildronate in ophthalmic disorders
Dubey et al. Management of neovascular glaucoma
US20190099401A1 (en) Method for protecting corneal endothelial cells from the impact caused by an eye surgery
Mohamed Hamed Ahmed et al. EVALUATION OF SHORT-TERM CHANGES IN CENTRAL CORNEAL ENDOTHELIAL CELL COUNT BY SPECULAR MICROSCOPE AFTER PHOTOREFRACTIVE KERATECTOMY (PRK) WITH MITOMYCIN-C (MMC) 0.02% IN PATIENT WITH MODERATE MYOPIA

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110601